{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-000579","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.639645+00:00","generated_at":"2026-06-07T04:31:35.663956+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Collegium 2024 guidance: revenue $580-595M, adj. EBITDA $380-395M, $150M buyback","bullets":["FY2024 product revenue net expected $580M-$595M; adjusted EBITDA $380M-$395M.","Board authorized $150M share repurchase program through June 30, 2025.","Xtampza ER gross-to-net improving to 56%-58% after renegotiations covering 30% of scripts.","Belbuca renegotiated major Medicare Part D contract, reducing rebate, and won new plan (~1M lives).","Returned $75M to shareholders in 2023 under prior buyback, including $25M accelerated repurchase."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-000579","json":"https://secwatch.observer/filing/0001104659-24-000579.json","markdown":"https://secwatch.observer/filing/0001104659-24-000579.md","text":"https://secwatch.observer/filing/0001104659-24-000579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924000579/0001104659-24-000579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924000579/tm241446d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:31:35.663956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}